Overview

Usual Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin on Coronary Atherosclerotic Plaque

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The aim of this prospective, open-label, randomized, single center study is to compare the effect of usual dose rosuvastatin plus ezetimibe and high-dose rosuvastatin on modifying atherosclerotic plaque.
Phase:
Phase 4
Details
Lead Sponsor:
Samsung Medical Center
Collaborators:
Hanmi Pharm. Co., Ltd.
Hanmi Pharmaceutical co., ltd.
Treatments:
Ezetimibe
Rosuvastatin Calcium